Total Funding
76
60
Total FundingVenture - Series Unknown raised
Growth Score
-5 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
65417
Oligon is an emerging biotechnology company developing a novel class of multimodal RNA therapeutics.
- James Silver: Chief Operating Officer
Daniel Von Hoff: Chief Clinical StrategistPast Role: University of Texas Health Science Center at San Antonio, Professor
About the Company
Oligon company provides emerging biotechnology services developing a novel class of multimodal RNA therapeutics. They provide RNA oligonucleotide consultants, research associates, and research scientists. Their contact is done through phone and email.
